All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
The Lymphoma Hub is happy to present a visual abstract representing key data from the phase I/II BRUIN trial (NCT03740529) evaluating the safety and efficacy of pirtobrutinib, a reversible (non-covalent) Bruton’s tyrosine kinase inhibitor, in heavily pretreated patients with relapsed/refractory Waldenstrom’s macroglobulinemia, as presented at the 64th American Society of Hematology Annual Meeting and Exposition. In June 2021, the Lymphoma Hub reported preliminary results of the trial.
To download this visual abstract, click below.Download here
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Treating Richter transformation in CLL
As there is no standardized treatment strategy for patients with Richter transformation, an unmet need exists for safe and effective novel therapies for this patient population. Here, we summarize new data...
Genomic pathways and treatment strategies for patients with Waldenstrom’s macroglobulinemia
Despite the rarity of WM there has been vast progression of WM treatments in both frontline and relapsed/refractory (R/R) settings. Advancements in...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox